Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease

References

• Mathers CD, Iburg KM, Begg S. Adjusting for dependent comorbidity in the calculation of healthy life expectancy. Popul Health Metr. 2006;4:4.
   PubMedGoogle Scholar
• Pinheiro MM, Pinheiro FM, Torres MA. Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Endocrinol Diabetes Metab Case Rep. 2016;2016.
   PubMedGoogle Scholar
• Mortensen H, Hougaard P, Swift P, et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 2009;32(8):1384–1390.
   PubMed Web of Science ®Google Scholar
• Davis SN, Tate D, Hedrington M. Mechanisms of hypoglycemia and exercise-associated autonomic dysfunction. Trans Am Clin Climatol Assoc. 2014;125:281–91; discussion 91–2.
   PubMedGoogle Scholar
• Diedrich L, Sandoval D, Davis S. Hypoglycemia associated autonomic failure. Clin Auton Res. 2002;12(5):358–365.
   PubMed Web of Science ®Google Scholar
• Cryer P. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54(12):3592–3601.
   PubMed Web of Science ®Google Scholar
• Sagoo M, Gnudi L. Diabetic nephropathy: is there a role for oxidative stress? Free Radic Biol Med. 2018;116:50–63.
   PubMed Web of Science ®Google Scholar
• Mogensen C. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;64–78.
   PubMed Web of Science ®Google Scholar
• Hovind P, Rossing P, Tarnow L, et al. Progression of diabetic nephropathy. Kidney Int. 2001;59:702–709.
   PubMed Web of Science ®Google Scholar
• Gnudi L, Gentile G, Ruggenenti P. The patient with diabetes mellitus. Oxford Textbook of Clinical Nephrology. 4th ed. UK: Oxford University Press; 2016.
   Google Scholar
• Middleton RJ FR, Hegarty J, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant. 2006;21(1):88–92.
   PubMed Web of Science ®Google Scholar
• New J, Middleton RJ, Klebe B, et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med. 2007;24(4):364–369.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox JCC. Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney® Scores. BMC Fam Pract. 2010;11(49):1–13.
   PubMedGoogle Scholar
• Nathan DM CP, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653.
   PubMed Web of Science ®Google Scholar
• Drury P, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54:32–43.
   PubMed Web of Science ®Google Scholar
• Foley R, Culleton BF, Parfrey PS, et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia. 1997;40:1307–1312.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. Nat Rev Endocrinol. 2015;11:289–297.
   PubMed Web of Science ®Google Scholar
• Griffin K, Thompson PA, Gottschalk M, et al. Combinatin therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicertre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;1(9):710–718.
   Google Scholar
• Deacon C, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333–347.
   PubMed Web of Science ®Google Scholar
• Zhong J, Gong Q, Goud A, et al. Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials. J Diabetes Res. 2015;197:170-179.
   Web of Science ®Google Scholar
• Jung C, Park C, Ahn K, et al. A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes Metab Res Rev. 2015;31(3):295–306.
   PubMed Web of Science ®Google Scholar
• Garber A. Incretin effects on beta-cell function, replication, and mass: the human perspective. Diabetes Care. 2011;34(Suppl 2):S258–63.
   PubMedGoogle Scholar
• Kim D, Whan L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihy-dro[1,2,4]triazolo(4,3-a)pyrazine-7[8H]-yl]-1-(2,4,5-trifluoro-phenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor in the treatment of type 2 diabetes. J Med Chem. 2005;48(1):141–151.
   PubMed Web of Science ®Google Scholar
• Coppolino G, Leporini C, Rivoli L, et al. Exploring the effects of DPP-4 inhibitors on the kidney fromthe bench to clinical trials. Pharmacol Res. 2018;129:274–294.
   PubMed Web of Science ®Google Scholar
• Deacon C. Dipeptidyl peptidase 4 inhibition with sitagliptin: A new therapy for Type 2 diabetes. Expert Opin Invest Drugs. 2007;16(4):533–545.
   PubMed Web of Science ®Google Scholar
• Herman G, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–688.
   PubMed Web of Science ®Google Scholar
• Lankas GR LB, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54(10):2988–2994.
   PubMed Web of Science ®Google Scholar
• Agency EM. Scientific Discussion for Vildagliptin. 2007.
   Google Scholar
• Agency EM. Assessment report for GLP-1 based therapies.
   Google Scholar
• Ahrén A, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775–783.
   PubMed Web of Science ®Google Scholar
• Villhauer EBBJ, Naderi GB, Burkey BF, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with anti hyperglycemic properties. J Med Chem. 2003;46(13):2774–2789.
   PubMed Web of Science ®Google Scholar
• Drucker D. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007;30(6):1335–1343.
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012;51(7):411–427.
   PubMed Web of Science ®Google Scholar
• Scheen A. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648–658.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Paldanium PM, Ayyagari R, et al. Systematic literature review of dpp-4 inhibitors in patients with type 2 diabetes mellitus and renal impairment. Diabetes Ther. 2016;7(3):439–454.
   PubMed Web of Science ®Google Scholar
• Kountz D. The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. Adv Ther. 2013;30(12):1067–1085.
   PubMed Web of Science ®Google Scholar
• Garg SK ME, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19(1):19–28.
   PubMed Web of Science ®Google Scholar
• Farngren J, Persson M, Schweizer A, et al. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(10):3799–3806.
   PubMed Web of Science ®Google Scholar
• Ellis SL, Moser EG, Snell-Bergeon JK, et al. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28(10):1176–1181.
   PubMed Web of Science ®Google Scholar
• Hari Kumar K, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100(2):e55–8.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Guglielmi C. Immunomodulation for the prevention of SPIDDM and LADA. Ann N Y Acad Sci. 2006;1079:90–98.
   PubMed Web of Science ®Google Scholar
• Falorni A, Gambelunghe G, Forini F, et al. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab. 2000;85(1):309–316.
   PubMed Web of Science ®Google Scholar
• Seissler J, de Sonnaville JJ, Morgenthaler NG, et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia. 1998;41(8):891–897.
   PubMed Web of Science ®Google Scholar
• Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8(5):1123–1134.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab. 2014;99(5):E876–80.
   PubMed Web of Science ®Google Scholar
• Johansen OE, Boehm BO, Grill V, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014;37(1):e11–2.
   PubMed Web of Science ®Google Scholar
• Buzzetti R, Pozzilli P, Frederich R, et al. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev. 2016;32(3):289–296.
   PubMed Web of Science ®Google Scholar
• Kozlovski P, Bhosekar V, Foley J. DPP-4 inhibitor treatment: beta-cell response but not HbA1c reduction is dependent on the duration of diabetes. Vasc Health Risk Manag. 2017;13:123–126.
   PubMed Web of Science ®Google Scholar
• Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clin Sci. 2018;132:489–507.
   PubMed Web of Science ®Google Scholar
• Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209–294.
   PubMed Web of Science ®Google Scholar
• von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens. 2014;23(1):54–60.
   PubMed Web of Science ®Google Scholar
• Chen YT, Wallace CG, Yang, CC, et al. DPP-4 enzyme deficiency protects kidney from acute ischemia-reperfusion injury: role for remote intermittent bowel ischemia-reperfusion preconditioning. Oncotarget. 2017;8(33):54821–54837.
   PubMedGoogle Scholar
• J OX L, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol. 2009;175(4):1380–1388.
   PubMed Web of Science ®Google Scholar
• Park CW, Kim, HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol. 2007;18(4):1227–1238.
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89(6):3055–3061.
   PubMed Web of Science ®Google Scholar
• Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15(3):197–207.
   PubMed Web of Science ®Google Scholar
• Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Ren Physiol. 2011;301(2):F355–63.
   PubMed Web of Science ®Google Scholar
• Sun AL, Deng JT, Guan GJ, et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res. 2012;9(4):301–308.
   PubMed Web of Science ®Google Scholar
• Girardi AC, Degray BC, Nagy T, et al. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem. 2001;276(49):46671–46677.
   PubMed Web of Science ®Google Scholar
• Girardi AC, Knauf F, Demuth HU, et al. Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol. 2004;287(5):C1238–C45.
   PubMed Web of Science ®Google Scholar
• Tiruppathi C, Miyamoto Y, Ganapathy V, et al. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem. 1990;265(3):1476–1483.
   PubMed Web of Science ®Google Scholar
• Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340(2):248–255.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Sato Y, Kamimoto T, et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol. 2009;200(1):53–61.
   PubMed Web of Science ®Google Scholar
• Mega C, de Lemos ER, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res. 2011;2011:162092.
   Google Scholar
• Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120–2131.
   PubMed Web of Science ®Google Scholar
• Shi S, Kanasaki K, Koya D. Linagliptin but not Sitagliptin inhibited transforming growth factor-beta2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition. Biochem Biophys Res Commun. 2016;471(1):184–190.
   PubMed Web of Science ®Google Scholar
• Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med. 2008;233(1):4–11.
   PubMed Web of Science ®Google Scholar
• Sun H, Yao W, Tang Y, et al. Urinary exosomes as a novel biomarker for evaluation of α-lipoic acid’s protective effect in early diabetic nephropathy. J Clin Lab Anal. 2017;31(6).
   Web of Science ®Google Scholar
• ADA. 10. Microvascular complications and foot care: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S105–S18.
   PubMedGoogle Scholar
• Duvnjak L, Perkovic M, Blaslov K. Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes. J Diabetes Complications. 2017;31(1):218–222.
   PubMed Web of Science ®Google Scholar
• Walker S, Komenda P, Khojah S, et al. Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials. Nephron. 2017;136(2):85–94.
   PubMed Web of Science ®Google Scholar
• Kamiya H. A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease. Hemodial Int. 2017;21(1):72–83.
   PubMed Web of Science ®Google Scholar
• Lovshin JA, Rajasekeran H, Lytvyn Y, et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha1-67 in patients with type 2 diabetes. Diabetes Care. 2017;40(8):1073–1081.
   PubMed Web of Science ®Google Scholar
• Ott C, Kistner I, Keller M, et al. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia. 2016;59(12):2579–2587.
   PubMed Web of Science ®Google Scholar
• Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017;19(11):1610–1619.
   PubMed Web of Science ®Google Scholar
• Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38(4):696–705.
   PubMed Web of Science ®Google Scholar
• Green JBBM, Bethel MA, Paul ,SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(6):983–989.e7.
   Web of Science ®Google Scholar
• Green JB BM, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• White WB BG, Bergenstal RM, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162(4):620–6 e1.
   PubMed Web of Science ®Google Scholar
• White WB CC, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335.
   PubMed Web of Science ®Google Scholar
• Scirica BM BD, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011;162(5):818–25 e6.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69-79.
   Google Scholar
• Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Med. 2017;130(6S):S4–S17.
   PubMedGoogle Scholar
• Pinheiro M, Stoppa CL, Valduga CJ, et al. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro. Eur J Pharm Sci. 2017;100:17–24.
   PubMed Web of Science ®Google Scholar
• Furukawa AWSA, Tang Q. Impact of immune-modulatory drugs on Treg. Transplantation. 2016;100(11):2288–2300.
   PubMed Web of Science ®Google Scholar
• Qiao YC, Shen J, Hong X Z, et al. Changes of regulatory T cells, transforming growth factor-beta and interleukin-10 in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Clin Immunol. 2016;170:61–9.
   PubMed Web of Science ®Google Scholar
• Scheen A. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387–405.
   PubMed Web of Science ®Google Scholar
• FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain 2015. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf.
   Google Scholar
• FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). 2014. Available from: https://wayback.archive-it.org/7993/20170113112103/http://www.fda.gov/downloads/Drugs/DrugSafety/UCM385315.pdf.
   Google Scholar
• Lee Y, Jun H. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642.
   PubMed Web of Science ®Google Scholar